|
|
Vol. 15.14 – 30 July, 2026
|
|
|
|
|
|
|
|
|
In this study, digital spatial profiling, multiplex immunofluorescence, and clinical data from 52 lung adenocarcinoma patients were integrated to develop organ-specific metastasis risk models, and the molecular mechanisms underlying metastatic organotropism were investigated. [Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators characterized the role of ADAM with Thrombospondin motifs 14 (ADAMTS14) in YAP-mediated fibroblast mechanoactivation and pulmonary fibrosis.
[American Journal of Respiratory and Critical Care Medicine]
|
|
|
|
|
|
|
|
Researchers identified pyruvate carboxylase as a pivotal ferroptosis regulator that is highly expressed in NSCLC tissues and associated with aggressive progression and poor prognosis.
[Cancer Letters]
|
|
|
|
|
|
Scientists revealed that phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) mRNA and protein levels were significantly increased in lung-adenocarcinoma tumor tissues compared to adjacent normal tissues.
[Oncogene]
|
|
|
|
|
|
The authors established tyrosine kinase inhibitor (TKI)-resistant variants by integrating cell lines, lung cancer organoids, and in vivo models, revealing the pivotal role of the NF-κB/ALDH1A1 signaling in mediating non-mutational TKI resistance.
[Oncogene]
|
|
|
|
|
|
M2‑like macrophages, IL‑4/IL‑13‑polarized THP‑1‑derived macrophages, were shown to release exosomes that lung cancer cells effectively internalized. These exosomes markedly enhanced the proliferation, migration, and invasion of lung cancer cells, thereby promoting malignancy. [Oncology Reports]
|
|
|
|
|
|
|
|
The authors frame lung cancer stem cells and the tumor immune microenvironment as a reciprocal regulatory network rather than as independent biological compartments. [Translational Oncology]
|
|
|
|
|
|
|
|
A new drug that treats NSCLC carrying a mutation called a ROS1 fusion has been approved by the US FDA. The drug zidesamtinib (Jideytro) was approved for patients with advanced ROS1-positive NSCLC who have stopped responding to other drugs aimed at ROS1. [Memorial Sloan Kettering Cancer Center]
|
|
|
|
|
|
|
|
August 27-30, 2026 Frankfurt, Germany
|
|
|
|
|
|
|
|
|
|
|
Thomas Jefferson University – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
Dartmouth Cancer Center – Lebanon, New Hampshire, United States
|
|
|
|
|
|
|
CICF International, Inc. – Maryland, United States
|
|
|
|
|
|
|
UmeÃ¥ University – UmeÃ¥, Sweden
|
|
|
|
|
|
|
Medical University of Vienna – Vienna, Austria
|
|
|
|
|
|